Post-genomic clinical trials: the perspective of ACGT. Tekijä Graf, N, Desmedt, C, Buffa, F, Kafetzopoulos, D, Forgó, N, Kollek, R, Hoppe, A, Stamatakos, G, Tsiknakis, M

Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analys... Tekijä Thompson, J, Kityo, C, Dunn, D, Hoppe, A, Ndashimye, E, Hakim, J, Kambugu, A, van Oosterhout, J, Arribas, J, Mugyenyi, P, Walker, A, Paton, N

HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa Tekijä Hoppe, A, Guilano, M, Lugemwa, A, Thompson, J, Floridia, M, Walker, A, Senoga, I, Abwola, M, Pirillo, M, Kityo, C, Arenas-Pinto, A, Paton, N

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the... Tekijä Paton, N, Kityo, C, Thompson, J, Nankya, I, Bagenda, L, Hoppe, A, Hakim, J, Kambugu, A, van Oosterhout, J, Kinconco, M, Bertagnolio, S, Easterbrook, P, Mugyenyi, P, Walker, A

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up resu... Tekijä Hakim, J, Thompson, J, Kityo, C, Hoppe, A, Kambugu, A, van Oosterhout, J, Lugemwa, A, Siika, A, Mwebaze, R, Mweemba, A, Abongomera, G, Thomason, M, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up resu... Tekijä Hakim, J, Thompson, J, Kityo, C, Hoppe, A, Kambugu, A, van Oosterhout, J, Lugemwa, A, Siika, A, Mwebaze, R, Mweemba, A, Abongomera, G, Thomason, M, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N

HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa Tekijä Kityo, C, Thompson, J, Nankya, I, Hoppe, A, Ndashimye, E, Warambwa, C, Mambule, I, van Oosterhout, J, Wools-Kaloustian, K, Bertagnolio, S, Easterbrook, P, Mugyenyi, P, Walker, A, Paton, N, For the Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST)Trial Team

Ethical considerations in global HIV phylogenetic research Tekijä Coltart, CEM, Hoppe, A, Parker, M, Dawson, L, Amon, JJ, Simwinga, M, Geller, G, Henderson, G, Laeyendecker, O, Tucker, JD, Eba, P, Novitsky, V, Vandamme, A-M, Seeley, J, Dallabetta, G, Harling, G, Grabowski, MK, Godfrey-Faussett, P, Fraser, C, Cohen, MS, Pillay, D

Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis Tekijä Ratmann, O, Grabowski, M, Hall, M, Golubchik, T, Wymant, C, Abeler-Dörner, L, Bonsall, D, Hoppe, A, Brown, A, De Oliveira, T, Gall, A, Kellam, P, Pillay, D, Kagaayi, J, Kigozi, G, Quinn, T, Wawer, M, Laeyendecker, O, Serwadda, D, Gray, R, Fraser, C, Pangea Consortium And Rakai Health Sciences Program

Assessment of second-line antiretroviral regimens for HIV therapy in Africa. Tekijä Paton, N, Kityo, C, Hoppe, A, Reid, A, Kambugu, A, Lugemwa, A, van Oosterhout, J, Kiconco, M, Siika, A, Mwebaze, R, Abwola, M, Abongomera, G, Mweemba, A, Alima, H, Atwongyeire, D, Nyirenda, R, Boles, J, Thompson, J, Tumukunde, D, Chidziva, E, Mambule, I, Arribas, JR, Easterbrook, P, Hakim, J, Walker, A, Mugyenyi, P